Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiog...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2023-09-01
|
| Serie: | Current Oncology |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1718-7729/30/9/628 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|